Xeris Biopharma Inc.

NASDAQ: XERS · Real-Time Price · USD
7.54
0.24 (3.29%)
At close: Aug 15, 2025, 1:14 PM

Xeris Biopharma Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
203.07M 163.91M 110.25M 49.59M
Cost of Revenue
36.83M 28.64M 22.63M 13.32M
Gross Profit
166.24M 135.27M 87.61M 36.27M
Operating Income
-33.65M -44.01M -81.94M -115.16M
Interest Income
5.32M 4.75M 2.58M 313K
Pretax Income
-57.1M -63.5M -96.08M -122.72M
Net Income
-54.84M -62.26M -94.66M -122.72M
Selling & General & Admin
163.48M 146.09M 137.75M 125.72M
Research & Development
25.56M 22.34M 20.97M 25.16M
Other Expenses
10.84M 10.84M 10.84M 550K
Operating Expenses
199.88M 179.28M 169.55M 151.43M
Interest Expense
33.17M 26.61M 14.1M 7.18M
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
236.72M 207.92M 192.19M 164.75M
Income Tax Expense
-2.27M -1.25M -1.42M n/a
Shares Outstanding (Basic)
146.77M 137.67M 135.63M 79.03M
Shares Outstanding (Diluted)
146.77M 137.67M 135.63M 79.03M
EPS (Basic)
-0.37 -0.45 -0.7 -1.55
EPS (Diluted)
-0.37 -0.45 -0.7 -1.55
EBITDA
-13.99M -23.73M -69.31M -113.67M
EBIT
-26.62M -36.9M -81.98M -115.55M
Depreciation & Amortization
12.63M 13.16M 12.67M 1.88M